Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

472
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
472
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Prevention02:59

Cancer Prevention

6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial dysfunction underlies cardiac contractility and growth defects in a zebrafish model of <i>NAA15</i>-related heart disease.

bioRxiv : the preprint server for biology·2026
Same author

Multi-omic mapping of Drosophila protein secretomes reveals tissue-specific origins and inter-organ trafficking.

Nature communications·2026
Same author

Luminal surface proteome of the brain vasculature uncovers blood-brain barrier regulators.

Science (New York, N.Y.)·2026
Same author

Integrative Multi-omics Analysis of the Human Skeletal Muscle Response to Endurance or Resistance Exercise: Findings from the Molecular Transducers of Physical Activity Consortium (MoTrPAC).

bioRxiv : the preprint server for biology·2026
Same author

Sensitive detection of cancer antigens enabled by user-defined peptide libraries.

Nature biotechnology·2026
Same author

Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.

Nature medicine·2026

Related Experiment Video

Updated: Oct 1, 2025

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.5K

Cancer proteogenomics: current impact and future prospects.

D R Mani1, Karsten Krug2, Bing Zhang3

  • 1Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA. manidr@broadinstitute.org.

Nature Reviews. Cancer
|March 3, 2022
PubMed
Summary

Proteogenomics integrates protein data with genomic information to understand cancer. This approach reveals new insights into tumor biology and potential therapeutic strategies.

More Related Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

866
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.1K

Related Experiment Videos

Last Updated: Oct 1, 2025

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.5K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

866
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.1K

Area of Science:

  • Oncology
  • Proteomics
  • Genomics

Background:

  • Genomic studies have identified cancer driver mutations but the function of most mutations and resistance mechanisms remain unknown.
  • Mass spectrometry-based proteomics now allows for direct analysis of genomic aberration consequences in tumors.
  • Proteogenomics integrates multi-omics data for deeper tumor characterization.

Purpose of the Study:

  • To review recent advancements in proteogenomics.
  • To highlight key findings from proteogenomic analyses across various cancers.
  • To discuss the application of proteogenomics in translational research and immuno-oncology.

Main Methods:

  • Utilizing mass spectrometry-based proteomics for quantitative tumor tissue characterization.
  • Integrating proteomic data with genomic, epigenomic, and transcriptomic information.
  • Describing technologies for generating, analyzing, and integrating proteomic and genomic data.

Main Results:

  • Proteogenomic analysis is yielding novel biological and diagnostic knowledge.
  • Understanding of malignant transformation and therapeutic outcomes is improving.
  • Emerging applications in translational studies and immuno-oncology.

Conclusions:

  • Proteogenomics offers a powerful approach to decipher the functional impact of genomic alterations in cancer.
  • This integrated multi-omics field holds significant potential for improving cancer diagnostics and therapeutics.
  • Full integration of proteogenomics into clinical trials and patient care is anticipated.